They say that an ounce of prevention is worth a pound of cure; knowing which preventive treatment to administer to which patient could undoubtedly up that yield.
Albumedix Ltd., an enabler of advanced therapies and the world leader in recombinant human albumin (rAlb), announced today that they have entered into a collaboration agreement with Cell and Gene Therapy Catapult (CGT Catapult) to investigate the use of Albumedix´ proprietary albumin-based solutions for advanced therapy applications, including viral vectors manufacturing.